Search Within

Gastrointestinal Oncology Service

Formats
  1. Journal Article (2351)
  2. Meeting Abstract (1870)
  3. Review (150)
  4. Book Section (127)
  5. Editorial (101)
  6. Guidelines (40)
  7. Correspondence (34)
  8. Conference Paper (24)
  9. Miscellaneous (23)
  10. Research Letter (17)
  11. Book Whole (12)
Groups
  1. Solid Tumor Oncology Division (4749)
  2. Department of Medicine (4747)
  3. Center for Pancreatic Cancer Research (2316)
  4. Surgery (1067)
  5. Survivorship Research (1014)
  6. Epidemiology and Biostatistics (843)

More Groups

People
  1. Eileen O'Reilly (804)
  2. Leonard Saltz (796)
  3. Ghassan Abou-Alfa (583)
  4. Nancy Kemeny (545)
  5. David Kelsen (538)
  6. David Ilson (443)

More People

Years
  1. 2025 (224)
  2. 2024 (309)
  3. 2023 (362)
  4. 2022 (346)
  5. 2021 (345)
  6. 2020 (326)

More Years

Publications
  1. Journal of Clinical Oncology (1290)
  2. Annals of Oncology (331)
  3. Annals of Surgical Oncology (148)
  4. Cancer (128)
  5. Clinical Cancer Research (107)
  6. Cancer Research (94)

More Publications

Publishers
  1. American Society of Clinical Oncology (1379)
  2. Oxford University Press (462)
  3. Elsevier Inc. (408)
  4. Springer (322)
  5. American Association for Cancer Research (281)
  6. Wiley Blackwell (241)

More Publishers

Results (4749)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • BEACON CRC: A randomized, 3-Arm, phase 3 study of encorafenib (ENCO) and cetuximab (CETUX) with or without binimetinib (BINI) versus choice of either irinotecan or FOLFIRI plus cetuximab in BRAF V600E-mutant metastatic colorectal cancer
    Meeting Abstract

    Desai, J.; Kopetz, S.; Grothey, A.; Van Cutsem, E.; Yaeger, R.; Wasan, H.; Yoshino, T.; Ciardello, F.; Gollerkeri, A.; Maharry, K.; more...
    Asia-Pacific Journal of Clinical Oncology (2019)

    Fulltext@MSK | Save
  • FIGHT-202: A phase II study of pemigatinib in patients (pts) with previously treated locally advanced or metastatic cholangiocarcinoma (CCA)
    Meeting Abstract

    Vogel, A.; Sahai, V.; Hollebecque, A.; Vaccaro, G.; Melisi, D.; Al-Rajabi, R.; Paulson, A. S.; Borad, M. J.; Gallinson, D.; Murphy, A. G.; more...
    Annals of Oncology (2019)

    Fulltext@MSK | Save
  • Health-related quality of life (HRQoL) impact of pembrolizumab (P) versus chemotherapy (C) as first-line (1L) treatment in PD-L1-positive advanced gastric or gastroesophageal junction (G/GEJ) adenocarcinoma
    Meeting Abstract

    Van Cutsem, E.; Valderrama, A.; Bang, Y. J.; Fuchs, C.; Shitara, K.; Janjigian, Y. Y.; Qin, S.; Larson, T.; Shankaran, V.; Stein, S.; more...
    Annals of Oncology (2019)

    Fulltext@MSK | Save
  • Encorafenib plus cetuximab with or without binimetinib for BRAF V600E-mutant metastatic colorectal cancer: Expanded results from a randomized, 3-arm, phase III study vs the choice of either irinotecan or FOLFIRI plus cetuximab (BEACON CRC)
    Meeting Abstract

    Tabernero, J.; Grothey, A.; Van Cutsem, E.; Yaeger, R.; Wasan, H.; Yoshino, T.; Desai, J.; Ciardiello, F.; Loupakis, F.; Sang Hong, Y.; more...
    Annals of Oncology (2019)

    Fulltext@MSK | Save
  • ClarIDHy: A global, phase III, randomized, double-blind study of ivosidenib (IVO) vs placebo in patients with advanced cholangiocarcinoma (CC) with an isocitrate dehydrogenase 1 (IDH1) mutation
    Meeting Abstract

    Abou-Alfa, G. K.; Macarulla Mercade, T.; Javle, M.; Kelley, R. K.; Lubner, S.; Adeva, J.; Cleary, J. M.; Catenacci, D. V.; Borad, M. J.; Bridgewater, J. A.; more...
    Annals of Oncology (2019)

    Fulltext@MSK | Save
  • CheckMate 459: A randomized, multi-center phase III study of nivolumab (NIVO) vs sorafenib (SOR) as first-line (1L) treatment in patients (pts) with advanced hepatocellular carcinoma (aHCC)
    Meeting Abstract

    Yau, T.; Park, J. W.; Finn, R. S.; Cheng, A. L.; Mathurin, P.; Edeline, J.; Kudo, M.; Han, K. H.; Harding, J. J.; Merle, P.; more...
    Annals of Oncology (2019)

    Fulltext@MSK | Save
  • POLO: Time to treatment discontinuation and subsequent therapies following maintenance olaparib for patients (pts) with a germline BRCA mutation and metastatic pancreatic cancer (mPC)
    Meeting Abstract

    Van Cutsem, E.; Golan, T.; Hammel, P.; Reni, M.; Macarulla, T.; Hall, M. J.; Park, J. O.; Hochhauser, D.; Arnold, D.; Oh, D. Y.; more...
    Annals of Oncology (2019)

    Fulltext@MSK | Save
  • Preliminary safety and pharmacokinetics of a new lysosomotropic oral agent, GNS561, in a first-in-human study in advanced primary liver cancer patients
    Meeting Abstract

    Awada, A. H.; Harding, J. J.; Kotecki, N.; Aftimos, P. G.; Decaens, T.; Dreyer, C.; Ansaldi, C.; Rachid, M.; Serdjebi, C.; Halfon, P.; more...
    Annals of Oncology (2019)

    Fulltext@MSK | Save
  • Effect of second-line cabozantinib on health states for patients with advanced hepatocellular carcinoma (aHCC) after sorafenib: QTWiST analysis from the CELESTIAL study
    Meeting Abstract

    Freemantle, N.; Abou-Alfa, G. K.; Cheng, A. L.; Kelley, R. K.; Valcheva, V.; Benzaghou, F.; Mollon, P.
    Annals of Oncology (2019)

    Fulltext@MSK | Save
  • GLOW: Randomized phase III study of zolbetuximab + CAPOX compared with placebo + CAPOX as first-line treatment of patients with CLD18.2(+)/HER2(-) locally advanced unresectable or metastatic gastric or gastroesophageal junction (GEJ) adenocarcinoma
    Meeting Abstract

    Shah, M.; Ajani, J. A.; Al-Batran, S. E.; Bang, Y. J.; Catenacci, D. V.; Enzinger, P.; Ilson, D.; Kim, S.; Lordick, F.; Shitara, K.; more...
    Annals of Oncology (2019)

    Fulltext@MSK | Save